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DCs control the adaptive immune response by 
providing a quantitative and qualitative frame-
work for T cell antigen recognition (1–3). DCs 
are present in a resting immature state and rapidly 
respond to microbial and infl ammatory stimuli 
by undergoing a maturation process that leads to 
their migration to secondary lymphoid organs, 
up-regulation of MHC and costimulatory mole-
cules, and production of T cell–polarizing cyto-
kines. Abundant data from the literature provide 
convincing evidence of the existence of multiple 
pathways of DC activation elicited by engage-
ment of a variety of receptors, including mem-
bers of the IL-1/Toll-like receptor (TLR) family 
and the TNF-R family (TNF-R and CD40; 
reference 4). It has been proposed that DCs are 
fl exible and adapt immune responses to invading 
pathogens according to the specifi c receptor en-
gaged and the presence of certain cytokines in 
the environment at the time of activation (5, 6).
Human monocyte-derived immature DCs 
(7) have been extensively used to identify mat-
uration stimuli and to study the interplay be-
tween synergizing and inhibitory stimuli. Based 
on their sensitivity and high grade of fl exibility, 
we thought of exploiting this cell system for 
the identifi cation and isolation of novel bioac-
tive compounds through bioassay-guided frac-
tionation of natural extracts.
Cyanobacteria, also termed blue-green al-
gae, are a large group of photosynthetic oxy-
genic prokariots with a high degree of biological 
adaptation. They represent one of the oldest 
forms of life on earth (8) and are a rich source 
of natural products with unique pharmacologi-
cal activities. Bioactive metabolites isolated 
from cyanobacteria have been found to display 
neuroprotective, cytotoxic, antibacterial, anti-
fungal, antiviral, and antiinfl ammatory properties 
(9–14). LPS derived from cyanobacteria and from 
Gram-negative bacteria diff ers in both chemi-
cal and biological characteristics. In general, 
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Toll-like receptors (TLRs) function as primary sensors that elicit coordinated innate immune 
defenses through recognition of microbial products and induction of immune and proin-
fl ammatory genes. Here we report the identifi cation and biological characterization of a 
lipopolysaccharide (LPS)-like molecule extracted from the cyanobacterium Oscillatoria 
Planktothrix FP1 (cyanobacterial product [CyP]) that is not stimulatory per se but acts as a 
potent and selective antagonist of bacterial LPS. CyP binds to MD-2 and effi ciently com-
petes with LPS for binding to the TLR4–MD-2 receptor complex. The addition of CyP 
together with LPS completely inhibited both MyD88- and TRIF-dependent pathways and 
suppressed the whole LPS-induced gene transcription program in human dendritic cells 
(DCs). CyP protected mice from endotoxin shock in spite of a lower capacity to inhibit LPS 
stimulation of mouse DCs. Interestingly, the delayed addition of CyP to DCs responding to 
LPS strongly inhibited signaling and cytokine production by immediate down-regulation of 
infl ammatory cytokine mRNAs while not affecting other aspects of DC maturation, such as 
expression of major histocompatibility complex molecules, costimulatory molecules, and 
CCR7. Collectively, these results indicate that CyP is a potent competitive inhibitor of LPS 
in vitro and in vivo and reveal the requirement of sustained TLR4 stimulation for induction 
of cytokine genes in human DCs.
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LPS from cyanobacteria lacks l-glycero-d-mannoheptose 
and phosphate groups, has long-chain saturated and unsaturated 
fatty acids, and very low content of 2-keto-3-deoxyoctonate 
(15–19). Furthermore, cyanobacterial LPS shows minimal or 
no toxicity in mice, whereas no data are available concerning 
its activity on human cells (16, 17).
In this study, we describe the biological activity of an 
LPS-like molecule extracted from the freshwater cyanobac-
terium Oscillatoria Planktothrix FP1, which we named CyP. 
We show that CyP is a potent antagonist of bacterial LPS, 
which, depending on the time of addition, can either com-
pletely block LPS-induced activation of DCs or prevent se-
cretion of cytokines without aff ecting phenotypic maturation. 
Notably, when tested in vivo, CyP is able to protect mice 
against lethal endotoxin shock. These results open promising 
perspectives for the use of CyP as a therapeutic agent able to 
modulate innate and adaptive immune responses and reveal 
the requirement of sustained TLR4 stimulation for induction 
of cytokine gene expression in human DCs.
RESULTS
Extracts from Oscillatoria Planktothrix FP1 potently inhibit 
the response of human DCs to LPS
Oscillatoria Planktothrix FP1 is a fi lamentous freshwater cya-
nobacterium isolated from an algal bloom in Lake Varese, 
Italy (20). To study the LPS of this cyanobacterium, extracts 
were prepared by a phenol and guanidinium thiocyanate–
based procedure as described previously (21), taking care of
removing free lipids, phospholipids, and protein  contaminants. 
The extracts represented 2% of cell dry weight and contained 
mainly an LPS-like product as detected in silver-stained 
 deoxycholate PAGE (DOC-PAGE; Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20060136/DC1) 
and to which we refer to as CyP hereafter. The 2-keto-
3-deoxyoctonate content of CyP was 0.15% (wt/wt), which 
is in the low range previously reported for LPS  isolated from 
other cyanobacteria, and the endotoxin activity, measured by 
the limulus amebocyte assay, was very low at 4 EU/μg as 
compared with 8,000 EU/μg of Salmonella abortus equi LPS 
and 15,000 EU/μg of Escherichia coli 055:B5 LPS.
CyP was compared with bacterial LPS for its capacity to 
stimulate human monocyte-derived DCs. Although E. coli 
LPS induced up-regulation of CD80, CD86, and CD83, 
CyP failed to do so (Fig. 1 A). Remarkably, however, 
when added with LPS, CyP was able to completely inhibit 
the LPS-induced up-regulation of these molecules. In ad-
dition, CyP did not induce cytokine (TNF, IL-6, IL-10, 
IL-12p35, and p40) and chemokine (CCL3, CCL5, and 
CCL19) gene transcripts but strongly inhibited their induc-
tion by LPS (Fig. 1 B and Fig. S2, which is available at 
http://www.jem.org/cgi/content/full/jem.20060136/DC1). 
Secretion of TNF and IL-6 proteins in LPS-stimulated DCs 
was inhibited in a dose-dependent fashion by the addition 
of CyP (Fig. 1 C). Furthermore, IL-10 was below the 
 detection limit in supernatants of CyP-treated cells as well 
as in supernatants of cells stimulated with LPS in the pres-
ence of CyP, whereas the inhibitory activity of CyP was 
still observed in the presence of anti–IL-10 blocking anti-
bodies, excluding CyP functions through IL-10 induction 
(unpublished data).
Figure 1. CyP inhibits LPS-induced activation of human DCs in a 
dose-dependent manner. (A) Human monocyte-derived DCs were 
treated with 1 μg/ml LPS and 20 μg/ml CyP alone or in combinations. 
After 16 h, expression of CD80, CD86, and CD83 was measured. Untreated 
DCs are shown in each panel as a gray profi le. One representative ex-
periment of six is shown. (B) Kinetics of TNF and IL-6 mRNA expression 
in DCs treated with LPS (▲), CyP (●), or LPS and CyP (▼) as measured 
by quantitative real-time RT-PCR. One representative experiment of 
fi ve is shown. Fig. S2 shows additional transcript analysis. (C) DCs were 
stimulated with 10 (white bars) or 1 (black bars) μg/ml LPS in the ab-
sence or presence of graded amounts of CyP. After 20 h, TNF and IL-6 
were measured in the culture supernatants by ELISA. One representative 
experiment of three is shown. (D) Nascent mRNA was isolated from the 
nuclei of DCs before (unst) and 1 or 3 h after stimulation by LPS in the 
absence (−) or presence (+) of CyP, and PCR was performed using 
 specifi c primers.
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On a weight basis, CyP behaved as a very potent inhibi-
tor because 50% inhibition of cytokine production could 
be elicited by concentrations of CyP 10-fold lower than 
LPS. Inhibition of cytokine and chemokine production 
was always >90%, regardless of the source of stimulatory 
LPS, which included several diff erent serotypes of E. coli, 
S. abortus equi, and Salmonella minnesota Re 595 (unpub-
lished data).
To understand whether CyP aff ects cytokine mRNA 
transcription and/or stability, we measured TNF and IL-6 
nascent mRNAs in the nuclei of DCs stimulated by E. coli 
LPS in the absence or presence of CyP. IL-6 gene transcrip-
tion was completely inhibited in the presence of CyP, whereas 
TNF gene transcription was not because the amount of na-
scent mRNA in untreated and CyP-treated DCs was compa-
rable (Fig. 1 D). These results suggest that CyP inhibits 
cytokine production by aff ecting both gene transcription and 
mRNA stability and are consistent with previous fi ndings 
showing that posttranscriptional mechanisms play a major 
role in the regulation of TNF expression in LPS-stimulated 
DCs (22).
We conclude that CyP behaves as a potent inhibitor of LPS-
induced DC-phenotypic maturation and cytokine production.
CyP is a selective inhibitor of LPS-induced activation of DCs
LPS induces DC maturation by triggering TLR4. Because 
DCs express several other receptors that can mediate matu-
ration and cytokine production, including TLRs, IL-1R, 
and CD40, we investigated whether CyP might interfere 
with DC activation induced by other stimuli. Although CyP 
completely inhibited TNF and IL-6 production by DCs 
stimulated with LPS, it did not interfere with that elicited by 
peptidoglican (PGN), poly(I:C), R848 (which trigger 
TLR2, TLR3, and TLR8, respectively) IL-1β, or CD40L 
(Fig. 2 A). CyP also failed to inhibit CpG-induced IFN-α 
release by plasmacytoid DCs (unpublished data), indicating 
that it does not interfere with TLR9 stimulation. These re-
sults indicate that CyP behaves as a selective inhibitor of the 
LPS–TLR4 axis.
Given the potent inhibitory activity of CyP on LPS stim-
ulation, we wondered whether CyP might be able to sup-
press activation of DCs by LPS-containing Gram-negative 
bacteria or by LPS combined with stimuli that have been 
shown to synergize in induction of IL-12p70 (23–25). When 
E. coli DH5α bacteria were titrated into DC cultures in the 
presence of CyP, a 700-fold increase in the number of bacte-
ria was required to elicit a comparable amount of TNF re-
lease (Fig. 2 B). In addition, when DCs were triggered by 
LPS in combination with IFN-γ, CD40L, or R848 in the 
presence of CyP, a marked inhibition of IL-12p70 produc-
tion was observed (Fig. 2 C), consistent with a complete ab-
lation of the LPS-dependent component.
Collectively, these experiments show that CyP specifi -
cally suppresses LPS-induced activation of DCs and by doing 
so it hampers mechanisms of amplifi cation of immune re-
sponses by agonists acting in synergy with LPS.
CyP inhibits LPS binding to the TLR4–MD-2 
receptor complex
Detection of LPS by immune cells depends upon the proper 
function of the TLR4–MD-2 receptor complex (26–28). 
 Although TLR4 is the signal transduction component of the 
LPS receptor, MD-2 has been shown to be the endotoxin 
binding unit (29–31). We therefore asked whether the inhib-
itory activity of CyP is mediated through inhibition of TLR4 
intracellular signaling or through competition for binding 
to the receptor complex. First, we transfected Jurkat cells 
with expression vectors encoding either TLR4, TLR9, or 
a chimera of extracellular TLR9 and intracellular TLR4 
( TLR9N4C; reference 32) and measured the activity of a 
luciferase reporter gene in response to LPS or CpG. CyP was 
able to inhibit the LPS response in TLR4-transfected cells 
but was ineff ective on the CpG-induced response of cells ex-
pressing the chimeric receptor (Fig. 3 A). Interestingly, the 
constitutive signaling of TLR4 transfectants that can be mea-
sured in the absence of LPS (33) was also inhibited by CyP 
(Fig. 3 B). Together with the fi nding that CyP did not aff ect 
Figure 2. CyP specifi cally inhibits LPS stimulation of DCs. (A) DCs 
were stimulated for 16 h with different TLR agonists (1 μg/ml LPS, 10 μg/ml 
PGN, 20 μg/ml poly(I:C), and 2.5 μg/ml R848), 20 ng/ml IL-1β, or 1 μg/ml 
soluble CD40L in the absence or presence of 20 μg/ml CyP. Data are ex-
pressed as the percentage of the response (TNF production, black bars; 
IL-6 production, white bars) obtained with the specifi c agonists in the 
absence of CyP and represent the mean ± SD of four independent experi-
ments. Inhibition of LPS was found to be statistically signifi cant (P < 0.0001), 
whereas inhibition of all other stimuli was found to be nonsignifi cant 
(P > 0.05). (B) DCs were challenged with graded numbers of DH5α bacte-
ria in the absence (white bars) or presence (black bars) of 20 μg/ml CyP. 
TNF was measured in the 20-h culture supernatants by ELISA. CyP did not 
affect bacterial growth. One representative experiment of three is shown. 
(C) DCs were stimulated with LPS, 10 ng/ml IFN-γ, soluble CD40L, or R848 
alone or in the indicated combinations in the absence (white bars) or 
presence (black bars) of CyP. IL-12p70 was measured in the 24-h culture 
supernatants. One representative experiment of four is shown.
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limulus amebocyte lysate activity of E. coli LPS (unpublished 
data), this result indicates that CyP acts at the extracellular 
level and does not function by complexing with LPS and 
neutralizing its activity.
Collectively, the data described above suggest that CyP 
directly interacts with the TLR4–MD-2 complex and hence 
interferes with LPS binding. To directly test this possibil-
ity, we used three diff erent experimental approaches. First, 
we incubated human monocytes that express high levels of 
 surface TLR4 and MD-2 with fl uorescent LPS in the pres-
ence of increasing concentrations of CyP. CyP inhibited in 
a dose-dependent fashion LPS binding with a 50% value 
being reached at a concentration 3.5-fold higher than that 
of LPS (Fig. 3 C and Fig. S3, which is available at http://
www.jem.org/cgi/content/full/jem.20060136/DC1). Sec-
ond, CyP was biotinylated and incubated with HEK293T 
cells  transfected with MD-2-FLAG. Precipitation of cell ly-
sates using streptavidin beads revealed the association of CyP 
Figure 3. CyP inhibits LPS at the level of MD-2–TLR4 extracellu-
lar domain. (A) Luciferase activity of Jurkat cells transfected with a 
3×NF-κB–driven luciferase reporter together with empty vector (Mock) 
or expression vectors encoding either TLR4, TLR9, or a chimera of extra-
cellular TLR9 and intracellular TLR4 (TLR9N4C) and stimulated with 1 μg/ml 
LPS or 3 μM CpG. Reporter activity was measured after 16 h of LPS 
 stimulation in the absence (white bars) or presence (black bars) of 20 μg/ml 
CyP. Similar results were obtained at 6 h of stimulation. Data represent 
the mean ± SD of duplicates of one experiment of two performed with 
identical results. (B) Spontaneous luciferase activity in Jurkat cells trans-
fected with a 3×NF-κB–driven luciferase reporter together with an 
empty vector (Mock) or an expression vector encoding TLR4. Reporter 
activity in the absence (white bars) or presence (black bars) of CyP was 
measured 40 h after transfection in a 6-h assay. (C) Monocytes were 
stained with LPS conjugated to Alexa Fluor 488 (0.25 μg/ml LPS-AF488) 
in the absence (thick line) or presence (thin lines) of increasing concen-
trations of CyP (0.25, 12.5, 125, and 250 μg/ml) and analyzed by FACS. 
Background fl uorescence of monocytes is shown as a gray profi le. One 
representative experiment of four is shown. Fig. S3 shows the EC50 of 
CyP inhibiting LPS binding. (D) HEK293T cells mock transfected or trans-
fected with MD-2–FLAG were either lysed and probed for MD-2 expres-
sion with anti-FLAG antibodies or treated with 20 μg/ml biotinylated 
CyP. Biotinylated CyP was then captured with immobilized streptavidin, 
and MD-2 coprecipitates were detected with anti-FLAG antibodies. 
Stripped blots were subsequently probed with anti–MD-2 antibodies. 
Arrows indicate specifi c bands of differentially glycosylated MD-2 
(reference 63). (E) Recombinant human MD-2 (1 μg/ml, fi xed concentra-
tion) was incubated in wells coated with CyP (left) or LPS (right) in the 
presence of increasing concentrations of soluble LPS or CyP (0.24, 0.74, 
2.22, 6.66, 20, and 60 μg/ml). MD-2 bound to the coated plate was then 
detected by a specifi c anti–MD-2 antibody followed by horseradish per-
oxidase–conjugated secondary antibody. EC50 values were calculated 
on sigmoidal dose–response curves (variable slope; R squared, 0.9953 
or 0.9939 and 0.9692 or 0.9996 for CyP and LPS on CyP or LPS coat, 
 respectively). Data shown are from one experiment of two performed 
with identical results.
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with MD-2, detected in Western blot by anti-FLAG or anti–
MD-2 antibodies (Fig. 3 D). Finally, we set up ELISA as-
says using coated LPS or CyP and anti–MD-2 antibodies and 
found that soluble recombinant MD-2 binds to LPS and CyP 
and that these bindings can be inhibited in a concentration-
 dependent fashion by both LPS and CyP (Fig. 3 E). Collec-
tively, these experiments are consistent with the notion that 
CyP functions as an LPS antagonist by competitively binding 
to MD-2.
CyP inhibits both MyD88-dependent and -independent 
signal transduction and gene expression
To ask whether CyP might behave as a partial antagonist, 
we analyzed the TLR4 signaling pathways and performed a 
global gene transcription analysis in DCs stimulated by LPS 
and CyP alone or in combination. At least two distinct in-
tracellular signaling pathways are activated by TLR4. The 
“MyD88-dependent” pathway requires the adaptor protein 
Mal (also known as TIRAP) and MyD88 to signal through 
IRAK and TRAF6 and lead to activation of NF-κB and 
mitogen-activated protein kinases, such as p38, ERK, and 
JNK. In contrast, the adaptor molecules TRAM and TRIF 
transduce “MyD88-independent” signaling through activa-
tion of IRF3, which is required for the induction of IFN-β 
synthesis (34). CyP inhibited LPS-induced activation of both 
MyD88-dependent and -independent pathways, as assessed 
by the almost complete inhibition of p38, ERK, and c-Jun 
phosphorylation (Fig. 4 A) as well as nuclear translocation of 
IRF3 (Fig. 4 B). Moreover, as expected for an inhibitor that 
prevents LPS binding and signaling through TLR4–MD-2, 
LPS-induced degradation of IRAK (an upstream event in 
signal transduction) did not occur in the presence of CyP 
(Fig. 4 A). Similarly, CyP prevented LPS-induced IκBα deg-
radation and subsequent induction, both indicative of NF-κB 
activation (Fig. 4 A). Of note, when DCs were cultured in 
the presence of CyP alone, MyD88, TRAF6, and IRAK ex-
pression were not aff ected (Fig. 4 C), indicating that CyP 
does not induce degradation of signaling components.
An Aff ymetrix microarray analysis showed that the addi-
tion of CyP to DCs had a very limited eff ect on gene tran-
scription (Fig. 5, A and B). After a 1- or 3-h treatment with 
CyP, only 7 and 8 genes, respectively, out of 12,656 ex-
pressed were signifi cantly (P < 0.05) up-regulated or down-
regulated (greater than twofold change) compared with 
unstimulated control (Table S1, available at http://www.
jem.org/cgi/content/full/jem.20060136/DC1). In contrast, 
LPS stimulation resulted in a signifi cant greater than twofold 
induction or suppression of 274 genes. Remarkably, cells 
challenged with LPS in the presence of CyP showed an al-
most complete suppression of all LPS–up-regulated or –down-
regulated genes, including the most responsive ones (Fig. 5 
and Table S1). These results indicate that CyP is a full TLR4 
antagonist and inhibits the entire LPS-induced activation 
program impeding all intracellular responses.
CyP inhibits cytokine gene expression when added several 
hours after LPS
The results described above indicate that CyP behaves as a 
potent and selective LPS receptor antagonist, implying that it 
exerts its activity when given before or together with LPS. 
Consistent with this notion, we found that CyP added 15 min 
or 1 h after LPS failed to inhibit the up-regulation of B7 
 costimulatory and MHC molecules (Fig. 6 A). Moreover, 
15-min stimulation by LPS was suffi  cient to induce high ex-
pression of CCR7. In line with this result, the T cell stimula-
tory capacity of LPS-matured DCs was inhibited when 
CyP was given together with LPS but was not aff ected by the 
delayed addition of CyP (Fig. 6 B).
In sharp contrast, LPS-induced cytokine production was 
dramatically altered even when CyP was added several hours 
after LPS (Fig. 6 C). In particular, a signifi cant (>60%) inhi-
bition of IL-12p70 and IL-6 was still observed when CyP 
Figure 4. CyP inhibits MyD88-dependent and -independent signaling. 
Immunoblot of cell lysates of DCs stimulated for different times with 
0.4 μg/ml LPS in the absence or presence of 20 μg/ml CyP (A and B) 
or with CyP alone (C). IRF3 in B was detected in the nuclear fraction. One 
representative experiment of four is shown.
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was added 6 h after LPS. This eff ect was further investigated 
by performing a detailed kinetics of cytokine mRNA levels. 
As shown in Fig. 6 D, at any time after LPS stimulation, the 
addition of CyP resulted in an abrupt decrease in the amount 
of TNF, IL-6, IL-12p40, and IL-12p35 mRNAs. It should 
be noted that for other induced genes, kinetics of inhibition 
of mRNA transcripts varied considerably, and in some cases 
(like CCL5) a 1-h LPS stimulation was suffi  cient to induce 
maximal expression (Fig. S4, available at http://www.jem.
org/cgi/content/full/jem.20060136/DC1, and unpublished 
data). In addition, CyP given 4 h after LPS led to a decrease 
of late phosphorilation of c-Jun and p38 as well as an increase 
in IκBα protein levels (Fig. 6 E).
Collectively, the results described above indicate distinct 
temporal requirements of TLR4 signaling in the induction of 
diff erent DC maturation programs. At variance with B7, 
MHC, and CCR7 induction, which can be triggered by a 
very brief TLR4 stimulation, prolonged TLR4 engagement 
is required to sustain expression of some cytokine genes. 
 Importantly, this sustained TLR triggering can be interrupted 
by the addition of a specifi c receptor antagonist, thus limiting 
cytokine production.
Figure 5. CyP inhibits LPS-induced gene expression. Affymetrix 
methodology was used for global analysis of gene transcription. DCs from 
two different donors were left untreated (control), treated with 20 μg/ml 
CyP for 1 or 3 h, or treated with 0.5 μg/ml ultrapure LPS in the absence or 
presence of CyP for 3 h. (A) Genes showing a statistically signifi cant 
change (P < 0.05) in at least one experimental condition versus control 
(321 genes) are ordered on the x axis according to decreasing “fold 
change” expression (relative to control) induced by LPS treatment. For 
each gene, the fold changes subsequent to different treatments are 
shown on the y axis. (B) Volcano plots of the fold changes between 
treated (1 h CyP, 3 h CyP, and 3 h LPS in the presence or absence of CyP) 
and untreated DCs for the 12,656 expressed genes. Green, transcripts with 
at least twofold up-regulation with P < 0.05; blue, transcripts with at 
least twofold down-regulation with P < 0.05; red, transcripts with fold 
change less than 2 or P > 0.05. See Table S1 for the list of all expressed 
gene transcripts.
 o
n
 April 4, 2012
jem.rupress.org
D
ow
nloaded from
 
Published May 22, 2006
JEM VOL. 203, June 12, 2006 1487
ARTICLE
CyP protects mice from lethal endotoxin shock
LPS plays a key role in Gram-negative sepsis by inducing 
production of cytokines, such as TNF, IL-6, and IL-1, which 
mediate hyperactivation of the infl ammatory system, ulti-
mately leading to death by endotoxin shock (35). The potent 
suppression of LPS-induced proinfl ammatory cytokine pro-
duction observed in vitro on human cells, the interference 
with LPS synergy with other stimuli in DC activation, and 
the eff ectiveness at late time points after stimulation prompted 
us to investigate whether CyP might inhibit LPS-induced 
endotoxin shock in mice.
Because some LPS antagonists such as lipid IVa are spe-
cies specifi c, in that they are antagonist on human cells but 
agonist on murine cells (36), we fi rst assessed the activity of 
CyP in vitro on the mouse macrophage line RAW 264.7 and 
on mouse bone marrow–derived DCs. In these cells, CyP did 
Figure 6. CyP interferes with LPS-induced cytokine production 
even when added several hours after LPS. DCs were stimulated with 
0.4 μg/ml LPS, and 20 μg/ml CyP was added at various time intervals. 
(A) Cells were analyzed for CD80, CD86, and HLA-DR 20 h after stimula-
tion and for CCR7 44 h after stimulation. Shadowed profi les correspond 
to unstimulated cells. One representative experiment out of fi ve is shown. 
(B) Graded numbers of DCs stimulated as in A were cultured with alloge-
neic naive CD4+ T cells, and proliferation was measured on day 5 by 
[3H]thymidine incorporation and expressed as cpm. Data represent the 
mean ± SD of duplicates of one experiment of four performed. (C) DCs 
were stimulated with LPS, and CyP was subsequently added at the indi-
cated time points. Cytokines released in the culture supernatants at 20 h 
were measured by ELISA and expressed as percentage of production in 
absence of CyP addition (−). Data represent the mean ± SD of three 
independent experiments. (D) DCs were stimulated with LPS in replicate 
cultures. The cells were left untreated (●) or CyP was added after 1 (▽), 
3 (◇), or 6 (○) h. The kinetics of cytokine-specifi c transcripts were deter-
mined by quantitative real-time RT-PCR. One representative experiment 
of three is shown. Fig. S4 reports the kinetics of CCL5 transcripts. (E) After 
4 h of LPS stimulation, DCs were left untreated or CyP was added to the 
culture. Cell lysates were prepared 20 min, 1 h, or 2 h after the addition of 
CyP and analyzed by Western blot with antibodies specifi c for phospho-
rilated c-Jun, phosphorilated p38, or IκBα.
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not show any agonistic activity and antagonized LPS-induced 
cytokine release, although the potency was 50–200-fold 
lower than that measured in human cells. Indeed, a 20-fold 
excess of CyP, which completely inhibited cytokine produc-
tion in human DCs, was able to reduce the production of 
TNF and IL-6 by mouse DCs from 35 to 75% in separate ex-
periments (unpublished data).
We then investigated whether CyP might protect mice 
from LPS-induced endotoxin shock. A group of mice was 
sensitized with d-galactosamine and injected i.p. with 25 ng 
LPS (Fig. 7 A). Within the fi rst 4 h, mice developed signs of 
endotoxemia and died within 8 h due to liver injury induced 
by TNF-dependent apoptotic death of sensitized hepatocytes 
(37). Coinjection of 750 μg CyP conferred signifi cant protec-
tion: mice showed milder signs of distress, death was delayed, 
and 58% of the mice survived (Fig. 7 A). In a second group 
of mice, endotoxin shock was induced in the absence of 
d- galactosamine sensitization by i.p. injection of 1.5 mg LPS 
(Fig. 7 B). In this setting, which better refl ects the complexity 
of endotoxin shock, mice developed ruffl  ed fur, diarrhea, ab-
normal secretion of eyes, ataxia, twitching, hunched posture, 
and lethargy, and death occurred between 24 and 40 h after in-
jection due to multi organ failure. Coinjection of 850 μg CyP 
conferred signifi cant protection from death in 80% of the mice 
that generally showed only mild signs of endotoxemia (Fig. 
7 B). No late death occurred over more than 1 wk, indicating 
that CyP did not merely delay the onset of LPS lethality. CyP 
also protected from i.p. injection of  bacteria and when given 
intravenously (unpublished data). Collectively, these results 
demonstrate that CyP exerts anti-endotoxin eff ects in vivo.
DISCUSSION
In this study, we functionally characterize a cyanobacterial 
LPS-like product (CyP) that acts as a potent and selective 
TLR4–MD-2 receptor antagonist. CyP is nontoxic at high 
concentrations on both human and mouse cells, and, when 
added to human DCs, it does not elicit any response detect-
able by global transcriptional analysis. Furthermore, when 
given together with LPS, CyP completely inhibits DC acti-
vation in vitro as well as endotoxic shock in vivo.
Several reports have described natural and synthetic in-
hibitors of LPS-induced infl ammatory responses in human 
cells, and some compounds are currently being tested in vivo 
(38, 39). These fall in two broad categories: receptor antago-
nists and LPS-neutralizing molecules. Among the fi rst are 
LPS-like molecules isolated from bacteria (Rhodobacter capsu-
latus and sphaeroides, Porphyromonas gingivalis, and Helicobacter 
pylori), deacylated LPS, lipid IVa, synthetic Lipid A analogues 
(including E5531, E5564, DT-5461, and GLA-47), and cer-
tain cationic peptides (40–49). LPS-neutralizing molecules 
include polymixin B and synthetic peptides (50–52). Some of 
the compounds listed above behave as agonists when given at 
high concentrations or in mice. In contrast, CyP is devoid of 
any agonistic activity even at high concentrations and acts as 
a pure LPS antagonist on human and mouse cells. Indeed, no 
lethality was observed in mice injected with up to 1 mg CyP 
even upon sensitization with d-galactosamine (unpublished 
data). It is worth noting that CyP behaves as a specifi c TLR4–
MD-2 antagonist and does not interfere with stimulation of 
other TLRs. However, by selectively inhibiting LPS, CyP 
removes a potent stimulus that synergizes with CD40L, IFN-γ, 
or R848 in DC activation (23–25). Remarkably, the inhibi-
tory eff ect of CyP is observed even when DCs are challenged 
with live Gram-negative bacteria.
It has recently been reported that the synthetic LPS 
 antagonist E5564 inhibits the binding of LPS to the TLR4–
MD-2 receptor complex (31). We found that CyP can 
directly bind to MD-2, and by doing so, it competitively 
inhibits binding of LPS. In addition, CyP directly binds to 
the LPS binding protein (unpublished data), indicating that 
it may subtract serum components that strongly enhance LPS 
activity. Thus, by targeting both essential and enhancing 
mediators of LPS responses, CyP may represent a promising 
candidate for the development of drugs to treat endotoxin-
dependent diseases.
The biological activity of CyP is likely to be ascribed to 
the LPS-like glycolipid that is visualized by silver staining of 
purifi ed extracts separated by DOC-PAGE. Indeed, CyP is 
obtained following a classical extraction procedure for LPS. 
Its activity is maintained after boiling, it behaves as a glyco-
lipid in chromatographic purifi cation procedures we are cur-
rently using, and fi nally, it binds to MD-2, LPS binding 
protein, and polymixin B (unpublished data). To date, only 
few LPSs from cyanobacteria have been isolated and chemi-
cally characterized. Compared with LPS from Enterobacteri-
aceae, cyanobacterial LPS from diff erent genera revealed 
peculiar sugar and fatty acid composition and was generally 
Figure 7. CyP inhibits LPS-induced endotoxin shock in mice. 
(A) C57BL/6 mice were sensitized with D-galactosamine and injected 
i.p. with 25 ng S. abortus equi LPS alone (13 mice, ◇) or in combination 
with 750 μg CyP (12 mice, ●). (B) C57BL/6 mice were injected i.p. with 
1.5 mg E. coli 055:B5 LPS alone (6 mice, ◇) or in combination with 850 
μg CyP (10 mice, ●). p-values calculated by the Kaplan-Meyer log-rank 
test are indicated.
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shown to be nontoxic when injected into mice (15–19). 
 Extracts from fi lamentous cyanobateria other than Oscillatoria 
Planktothrix FP1 (Oscillatoria Neglecta, environmentally isolated 
Oscillatoria Sp. CCAP1459-26, and Leptolyngbya Sp.) were 
not stimulatory on human DCs but were not able to suppress 
LPS-induced activation (unpublished data), indicating that 
the LPS antagonistic activity is a distinct property of CyP.
A striking fi nding made in our study is that CyP exerts its 
inhibitory activity on cytokine production even when given to 
maturing DCs several hours after LPS. Biochemical studies 
showed that CyP added 4 h after LPS led to a sharp decrease in 
c-Jun and p38 phosphorylation, providing a mechanistic basis 
for the inhibition of cytokine production (53–55). We also 
found that a very short TLR4 stimulation (CyP added 15 min 
after LPS) was suffi  cient to induce full phenotypic maturation 
of DCs with acquisition of T cell stimulatory capacity, but did 
not lead to signifi cant production of TNF, IL-6, and IL-12p70. 
In contrast, these cytokines were induced only in response to 
sustained TLR stimulation. These results reveal the existence of 
distinct thresholds for the induction of surface markers versus 
cytokines and are consistent with the existence of a temporal 
window during which signals emanated from TLR4 are kinet-
ically integrated before they convey into a specifi c response.
Several recent studies examined the impact of the ki-
netics of receptor stimulation on expression of immune re-
sponse genes. It has been shown that accessibility of NF-κB 
to the promoter of early- and late-induced genes depends 
on the state of histone acetylation (56). In that study, a short 
stimulation was suffi  cient to recruit NF-κB to the promoter 
of IκBα and other constitutively and immediately accessible 
genes, but not to the promoter of late genes that need to be 
acetylated to become transcriptionally competent. Another 
study showed that a transient stimulus was not suffi  cient to 
ensure NF-κB activity at late time points due to the rapid 
induction of IκBα that provides a rapid negative feedback 
on NF-κB activity (57). Further evidence that specifi city 
in gene expression could be accomplished by using signal 
transduction pathways in temporally distinct ways came from 
computational modeling of signaling events downstream 
of TLR4 (58). Based on these and our results, we specu-
late that sustained TLR stimulation is required to maintain 
NF-κB activity in spite of IκBα resynthesis at late time points 
when some genes, such as IL-12, become transcriptionally 
 accessible. Consistent with this model, we found that if CyP 
is added at late time points during a response to LPS, IκBα 
protein levels increase, suggesting that CyP inhibits ongoing 
IκB degradation. It is also possible that the expression of late 
genes might also require synthesis of transcription factors that 
synergize with NF-κB.
It was recently shown that TLR stimulation is absolutely 
required for the generation of fully activated “eff ector” DCs 
capable of directing T cell diff erentiation, whereas infl amma-
tory cytokines are not suffi  cient (59, 60). Our results reveal 
that besides nature and concentration of microbial stimulus, 
duration of TLR stimulation is a previously unappreciated 
parameter that critically contributes to the eff ector function 
of DCs by regulating the expression of selected cytokine 
genes, such as IL-12. It will be interesting to assess the func-
tional consequences of the split of DC maturation induced by 
transient TLR triggering, especially for the magnitude and 
quality of T cell response and generation of memory (61).
In conclusion, our fi ndings indicate that a TLR recep-
tor antagonist can be used to block endotoxin shock in vivo 
and to modulate DC maturation in vitro, revealing for the 
fi rst time a requirement of sustained TLR stimulation for the 
expression of a selected set of immunoregulatory genes in 
maturing DCs. These results suggest that CyP might be a 
candidate for the development of a therapeutic agent able to 
control endotoxin shock and modulate immune responses.
MATERIALS AND METHODS
Extracts from cyanobacteria. Cultures from cyanobacterium Oscillatoria 
Planktothrix FP1 were grown in 250-ml fl asks containing 150 ml of BG11 
medium (Sigma-Aldrich) at 27°C under constant irradiance of cool white 
light at an intensity of 20 μmol.m−2.s−1 until stationary phase was reached. 
Microorganisms were then collected by centrifugation and frozen before 
processing with TRI reagent (Sigma-Aldrich) according to a method de-
scribed previously (21). Extracts in the acqueous phase were precipitated 
with 10 mM sodium acetate and 2 volumes of acetone and recovered by 
centrifugation at 2,000 g for 10 min. Pellets were washed twice with 70% 
ethanol to remove phospholipids, digested overnight at 37°C with 100 μg/ml 
proteinase K in 25 mM Tris, pH 8.5, to remove protein contaminants, 
and subjected to Folch partition to remove free lipids. Purifi ed extracts 
(named CyP) were then dissolved in PBS at 2 mg/ml. The biological activity 
was not aff ected by boiling the solution for 15 min or by repeated freezing 
and thawing.
Isolation and stimulation of DCs. Buff y coats were obtained from the 
Swiss Blood Center, Basel. Permission to do experiments on human primary 
cells was obtained from the Federal Offi  ce of Public Health. Monocytes 
were purifi ed from peripheral blood mononuclear cells by positive sorting 
using anti-CD14–conjugated magnetic microbeads (Miltenyi Biotec). DCs 
were generated as described previously by culturing monocytes in RPMI 
10% FBS supplemented with granulocyte/macrophage colony-stimulating 
factor and IL-4 (7). Cells were stimulated with LPS extracted from E. coli 
(serotypes 026:B6, 055:B5, and 0111:B4; Sigma-Aldrich) or S. abortus equi 
(S-form, pure TLR4 agonist; Qbiogene) at concentrations ranging from 0.4 
to 10 μg/ml as specifi ed in the fi gure legends. Alternatively, cells were stim-
ulated with 10 μg/ml PGN (Sigma-Aldrich), 20 μg/ml poly(I:C) (GE 
Healthcare), 2.5 μg/ml CpG 2006 (5′-T C G T C G T T T T G T C G T T T T G T-
C G T T -3′ phosphorotioate; Microsynth), 2.5 μg/ml R848 (GLSyhthesis), 
1 μg/ml CD40L plus 1 μg/ml Enhancer (Qbiogene), 20 ng/ml IL-1β 
(R&D Systems), or 10 ng/ml IFN-γ (provided by Roche).
FACS analysis. The following monoclonal antibodies were used: anti-
CD80 (MAB104), anti-CD83 (HB15a; Immunotech), anti-CD86 (IT2.2: 
BD Biosciences), and anti–HLA-DR (clone HB55; American Type Cul-
ture Collection [ATCC]) followed by appropriate rat anti–mouse IgG1 
(BD Biosciences) or goat anti–mouse IgG2a or IgG2b conjugated to FITC 
(SouthernBiotech) secondary antibodies; and anti-CCR7 (3D12; provided 
by M. Lipp, Max Delbroeck Center, Berlin, Germany) followed by  biotin-
conjugated mouse anti–rat IgG2a (BD Biosciences) and APC-conjugated 
streptavidin (Invitrogen). Samples were analyzed on a FACSCalibur cy-
tometer (Becton Dickinson) using propidium iodide (Sigma-Aldrich) to 
exclude dead cells.
Cytokine detection. Cytokine production was measured in the superna-
tants of DCs (0.5 × 106 cells/ml) stimulated for 16–24 h using matched 
paired antibodies specifi c for human TNF, IL-6, and IL-12p70 (DuoSet 
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ELISA development kits; R&D Systems). Data shown are from measure-
ments with standard deviations <5%.
Real-time fl uorogenic RT-PCR. Total RNA was isolated with the 
RNeasy kit (QIAGEN). cDNA was synthesized with random hexamers 
( Invitrogen) and MMLV (Invitrogen Life Technologies). Gene expression 
was determined by real-time fl uorogenic PCR with the ABI PRISM 7700 
Sequence Detection System (Applied Biosystems) by using predesigned 
TaqMan Gene expression assays and reagents according to the  manufacturer’s 
instructions (Applied Biosystems). For each sample, mRNA expression lev-
els for specifi c transcripts were normalized to the amount of 18S rRNA and 
expressed as arbitrary units.
Analysis of nascent transcripts. Nascent transcripts were isolated as de-
scribed previously (62) starting from 2.5 × 106 cells, lysing nuclei in 850 μl 
and extracting chromatin in 1 ml TRIzol (Invitrogen Life Technologies). 
Samples were treated with 20 U DNase I, RNase-free (Roche), in the 
presence of 80 U RNase OUT (Invitrogen) for 1 h at 37°C, extracted with 
TRIzol, and dissolved in water. PCR for specifi c transcripts was performed 
using the following primers: TNF, 5′-G A T G G T A G G C A G A A C T T G G A-
G A C -3′ (located in intron 3–4) and 5′-C A G C T G G T T A T C T C T C A G C-
T C C A -3′; and IL-6, 5′-A A A T T C G G T A C A T C C T C G A C G G C -3′ and 
5′-T G G T G G G C T C T G A G G T A T G A A T C -3′ (located in intron 2–3). 
β-actin was amplifi ed as internal control (5′-T C A C C C A C A C T G T G C C C-
A T C T A C G A -3′ and 5′-C A G C G G A A C C G C T C A T T G C C A A T G G-3′). 
Contamination of genomic DNA was always tested and found to be below 
the detection limit.
Transfection assays. Jurkat cells (expressing TLR9 and MD-2) were trans-
fected with 2 μg expression vectors encoding TLR9, a fusion of extracellular 
TLR9, and intracellular TLR4 (TLR9N4C; provided by R. Medzhitov, 
Yale University, New Haven, CT), or TLR4 together with 2 μg of 
3×NF-κB Luc reporter vector (provided by G. Natoli, IFOM, Milano, 
 Italy).  Transfection was performed with FuGENE6 according to the manu-
facturer’s instructions (Roche). After 16 h, cells were washed, resuspended 
in 12 ml, and plated in a 12-well plate with 1 ml of cells for each stimulatory 
condition (1 μg/ml LPS or 3 μM CpG 1826 5′-T C C A T G A C G T T C C T G-
A C G T T -3′ in the absence or presence of 20 μg/ml CyP). After a 6- or 16-h 
stimulation, cells were harvested and lysed, and reporter gene activity was 
measured using the Luciferase Assay System (Promega) and Veritas lumi-
nometer (Turner BioSystems).
LPS binding assay. LPS binding assay was performed on freshly isolated 
monocytes as described previously (41). In brief, cells were preincubated for 
30 min at 37°C in 180 μl SEBDAF buff er (20 mM Hepes, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 300 μg/ml BSA, 10 mM NaN3, 2 mM NaF, 5 mM 
deoxyglucose) to prevent ligand internalization. Appropriate dilutions of 
CyP were prepared in 20 μl FBS containing 2.5 μg/ml E. coli 055:B5 LPS 
conjugated to Alexa Fluor 488 (Invitrogen) and added to the samples to pro-
duce the fi nal concentrations indicated in Fig. 3 C. After 30 min of incuba-
tion at 37°C, cells were centrifuged and washed once in ice-cold buff er 
before FACS analysis.
MD-2 binding assays. Detection of binding of CyP to surface MD-2 was 
performed in HEK293T cells (ATCC) transfected with pEFBOS expression 
vector encoding human MD-2-FLAG-His6 (provided by K. Miyake, Uni-
versity of Tokyo, Japan), according to previously described procedures (31). 
In brief, CyP was labeled using biotin hydrazide according to the manufac-
turer’s instructions (Pierce Chemical Co.) and added to cells at 20 μg/ml for 
1h at 37°C. Immobilized streptavidin (Pierce Chemical Co.) was then added 
to cell lysates (20 mM Tris, pH 7.4, 137 mM NaCl, 1% Triton X-100, 
2 mM EDTA, 10% glycerol) and captured complexes separated on SDS-
PAGE under reducing conditions, blotted, and probed with anti-FLAG 
(M2; Sigma-Aldrich) or anti–MD-2 (R&D Systems) antibodies.  Alternatively, 
binding of MD-2 to CyP and competitive inhibition of the binding of 
MD-2 to LPS was studied in ELISA assays. LPS from E. coli 055:B5 or CyP 
(30 μg/ml in PBS) was coated overnight at 37°C on MaxiSorp 96-well plates 
(Nunc). After blocking with 0.05% BSA in wash buff er (50 mM Hepes, 150 
mM NaCl), dilutions of LPS or CyP (as indicated in Fig. 3 E) in 1 μg/ml re-
combinant human MD-2 (R&D Systems) were added to the plates for 2 h 
30 min at 37°C. MD-2 bound to coated LPS or CyP was then detected by 
incubation with 2 μg/ml mouse anti–human MD-2 fi rst, followed by horse-
radish peroxidase–conjugated sheep anti–mouse IgG secondary antibody 
(GE Healthcare). Plates were developed by the addition of 300 μg/ml 2,2′-
Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)diammonium salt (Sigma-
Aldrich) in 0.1 M citric acid, pH 4.35, 0.03% hydrogen peroxide.
Immunoblot analysis. Equal amounts of protein lysates were separated by 
SDS-PAGE and transferred onto nitrocellulose membranes. Filters were 
blocked with 5% dry skim milk and probed with the following specifi c pri-
mary antibodies: anti-MyD88 and anti-IκBα (Imgenex); anti-TRAF6, anti-
IRF3, anti-IRAK-1, and anti-total p38 (Santa Cruz Biotechnology, Inc.); 
and anti-phosphoJun (Ser73; Upstate Biotechnology), anti-diphosphorilated 
ERK-1 and -2, and anti-diphosphorilated p38 (Sigma-Aldrich). Blots were 
then incubated with appropriate horseradish peroxidase–conjugated donkey 
anti–rabbit IgG or sheep anti–mouse IgG secondary antibody (GE Health-
care) and developed with SuperSignal WestPico chemiluminescence Sub-
strate (Pierce Chemical Co.).
Microarray and data analysis. DCs from two diff erent donors were left 
untreated or treated with either 20 μg/ml CyP for 1 or 3 h or 0.5 μg/ml 
LPS from S. abortus equi S-form in the presence or absence of CyP for 3 h. 
RNA was extracted with the TRIzol method (Invitrogen Life  Technologies). 
5 μg total RNA was labeled and hybridized with GeneChip Expression 3′ 
Amplifi cation One-Cycle Target Labeling kit on Aff ymetrix U133 2.0 Plus 
microarrays (Aff ymetrix). Washes and scanning were performed according 
to Aff ymetrix protocols with Fluidics Station 400 and GeneChip Scanner 
3000. Raw signals and the “present” or “absent” calls were obtained using 
Aff ymetrix GCOS 1.2 software. Additional data analysis was performed with 
GeneSpring 7.2 (Silicon Genetics). Signal values <0.01 were set to 0.01. 
The percentile of all the measurements in each sample was calculated using 
all genes not marked absent, and each gene measurement was divided by the 
50th percentile. Each gene was then divided by the mean of its normalized 
measurements in the two untreated samples. Genes that did not present a 
signal intensity >50 and that were not marked as present in at least one con-
dition of each replicate were discarded: 12,656 probes out of 54,675 passed 
this fi lter. “Fold changes” between treated and untreated cells at 1 and 3 h 
were calculated on the 321 genes showing a statistically diff erential expres-
sion in at least one of the conditions using a parametric test with variance as-
sumed equal (ANOVA) and a p-value cut-off  of 0.05, followed by the 
Benjamini and Hochberg false discovery rate multiple test correction, and a 
Tukey Post Hoc test. Accession code GEO: GSE4748.
Sorting and priming of naive T cells. Naive CD4+ T cells were sorted 
from peripheral blood mononuclear cells with anti-CD4 magnetic beads (Milt-
enyi Biotec), followed by positive selection of cells stained with PE-conjugated 
CD45RA antibody (Immunotech). DCs were stimulated for 12 h with LPS in 
the absence or presence of CyP, washed, and irradiated (40 Gy), and graded 
numbers were plated with 37,500 allogeneic naive T cells. After 4 d, 4 μCi/ml 
of [methyl-3H]thymidine (GE Healthcare) was added for the last 12 h.
LPS-induced endotoxin shock in mice. All animal experiments were 
performed in accordance with approved protocols specifi ed in the permission 
obtained from the Swiss Federal Veterinary Offi  ce. Mice used in all survival 
studies were 8–10-wk-old C57BL/6 females (Charles River  Laboratories). 
In the d-galactosamine–sensitized model, mice were injected i.p. with 
20 mg d-galactosamine (Sigma-Aldrich) with 25 ng LPS from S. abortus equi 
(S-form) alone or in combination with 750 μg CyP diluted in PBS. Alterna-
tively, mice were injected i.p. with 1.5 mg LPS from E. coli serotype 055:B5 
diluted in PBS with or without 850 μg CyP.
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Statistical analysis. Statistical signifi cance was assessed by Student’s paired 
t test. Diff erences with p-values of <0.05 were considered statistically signif-
icant. The concentration of competitor that competes for half of the specifi c 
binding (EC50) was calculated on sigmoidal dose–response curves (variable 
slope). Datasets of survival curves were analyzed by the Kaplan-Meyer log-
rank test. Statistical analysis was conducted using Prism 4 GraphPad software.
Online supplemental material. Purity of phenolic extracts from cyano-
bacterium Oscillatoria Planktothrix FP1 (CyP) was evaluated by separation on 
DOC-PAGE and silver staining as shown in Fig. S1. Fig. S2 shows kinetics 
of cytokine and chemokine gene expression induced by LPS in the presence 
of CyP and complements data from Fig. 1 B. The EC50 of CyP- inhibiting 
binding of LPS-AF488 to monocytes shown if Fig. 3 C is calculated in 
Fig. S3. Kinetics of CCL5 mRNA induction upon LPS stimulation in the 
presence of CyP complements the data of Fig. 6 D and is shown in Fig. S4. A 
list of all 12,656 probe sets that in microarray analysis were marked as present 
in at least one condition can be found in Table S1. The supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20060136/DC1.
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